top of page

Government Needs to Encourage – Not Suppress – Drug Competition


By Dan Leonard


Six new copycat versions of Humira – one of the top-selling prescription drugs in the United States – just hit the market. Cyltezo is the first interchangeable Biosimilar for Humira, and another named Yusimry, is about 85% cheaper than the brand-name product. In total there will be eight available Biosimilar competitors to Humira available in the coming weeks...




We Work For Health brings together national and local business leaders, labor, biopharma, patient advocacy, and other healthcare-related stakeholders to support policies and initiatives that foster innovation and facilitate the delivery of lifesaving and life-enhancing medicines. 

We Work For Health. © 2023 All Rights Reserved.

bottom of page